Educational content, not medical advice. This article compares the prescribing information for two oral medicines for weight management. It does not recommend either product, it makes no efficacy comparison, and decisions between medicines belong to a prescriber and the person taking them.

There are two once daily GLP-1 pills approved for weight management, and they describe two different days. One begins with a fasted stomach, a precise amount of water and a half hour of waiting before breakfast. The other begins whenever the day begins, with or without food, and asks only that the tablet be swallowed whole. Anyone stepping from one to the other, or weighing a first prescription, will find the labels disagree less about the medicine than about the morning around it.

The molecules are different, semaglutide in one bottle and orforglipron in the other, and no trial has set them against each other. What each label does carry is a precise description of what the treatment asks of the person taking it, and those asks diverge almost immediately. Each medicine also has its own full guide: Foundayo (Orforglipron): The Daily GLP-1 Pill, Explained and Wegovy Tablets: What Changes When Semaglutide Is a Pill.

The morning ritual belongs to one label

Wegovy tablets carry the oral semaglutide rules, the strictest daily instructions in the class and the same ones printed for Rybelsus and Ozempic tablets. Foundayo's instructions fit in one breath. Set side by side, the two routines look like this.

Wegovy tabletsFoundayo
WhenOnce daily, in the morning, on an empty stomachOnce daily, with or without food
WaterWith water, up to 4 ounces, and no other liquidNo water rule on the label
WaitingAt least 30 minutes before food, beverages or other oral medicinesNo waiting period on the label
The tabletSwallow whole, never split, crush, chew or dissolveSwallow whole, do not break, crush or chew
AmountNo more than one tablet a dayNo more than one tablet a day

One shared rule deserves its own emphasis, because it is the one people get wrong when a tablet is hard to swallow: neither label permits splitting, crushing or dissolving. On Wegovy tablets the fasting rules point back to the label's absorption section, and they leave no room for improvisation. Foundayo's freedom on food timing is not leniency on the tablet itself.

One destination versus a range

The dose ladders are shaped differently, and the difference is easy to state. Wegovy tablets name a single destination: 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, and the 25 mg maintenance dosage from day 91 onward. Foundayo begins at 0.8 mg, goes to 2.5 mg after at least 30 days, then 5.5 mg after at least 30 days more, and from there the label allows an increase to the next level, 9 mg, 14.5 mg or 17.2 mg, after at least 30 days on the current dosage, based on treatment response and tolerability. The maximum Foundayo dosage is 17.2 mg once daily.

So one label prints a staircase to one fixed rooftop, and the other prints three mandatory rungs with three optional ones above them. Where any person stops is a prescriber's decision made on response and tolerability, and the numbers are meaningless across molecules: a Foundayo milligram and a Wegovy milligram share nothing but the word. How titration works across the whole class, and why every ladder climbs by the month, is laid out in GLP-1 Titration Schedules Explained, Medication by Medication.

GLP 1 Tracker AppLog a daily pill against its real titration ladder, keep a weight trend beside it, and get a reminder when the day's dose is due. Get the app

Missed doses, opposite in spirit

The missed-dose instructions read almost like mirror images. For Wegovy tablets: skip the missed dose and take the next dose the following day. For Foundayo: take the dose as soon as possible, do not double up the next dose, and if 7 or more consecutive doses are missed, restart dosage escalation at a lower dosage. One label says let it go until tomorrow; the other says take it late, and counts the length of a gap before restarting the climb.

Neither rule is a strategy to manage, and neither is a reason to take two tablets, which no label in this class ever permits. What the contrast does show is that habits cannot be carried blindly from one pill to the other. The general subject of missed GLP-1 doses and what official guidance says about them, injection or oral, is covered in Missed Your GLP-1 Dose? What the Official Guidance Says.

Interaction rules only one label carries

Both labels note the same underlying physiology: the medicine delays gastric emptying and so may affect the absorption of other oral medicines taken at the same time. Wegovy's label suggests considering increased clinical or laboratory monitoring for oral medicines with a narrow therapeutic index or that require monitoring. That is caution wording, addressed to a clinician.

Foundayo carries a second set of rules that Wegovy tablets do not have, because orforglipron interacts with drug metabolizing enzymes. Per the label: the maximum Foundayo dosage is 9 mg once daily when it is used with a strong CYP3A4 inhibitor; strong CYP3A4 inhibitors that also inhibit OATP1B should be avoided; strong CYP3A4 inducers should be avoided; Foundayo effectiveness should be monitored with moderate CYP3A4 inducers; and simvastatin should not exceed 20 mg once daily when taken with Foundayo. None of that is worth memorizing. It is worth knowing that it exists, because anyone already taking other medicines has a concrete reason to review the whole list with a prescriber or pharmacist before starting Foundayo.

Approved uses and the warning in the box

Both products are indicated for weight management in adults, in combination with a reduced calorie diet and increased physical activity, for adults with obesity or overweight in the presence of at least one weight-related comorbid condition. Wegovy tablets carry an additional indication: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. That cardiovascular indication belongs to Wegovy and not to Foundayo, and it is a record of what was studied for each product, not a ranking. Both medicines are adults-only as tablets; Wegovy's pediatric indication belongs to the injection.

Both carry the thyroid C-cell tumor boxed warning, the same contraindication for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and the same counseling language, including the note that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection. The premise printed above the contraindication differs. Wegovy's boxed warning says semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures, and that it is unknown whether Wegovy causes them in humans. Foundayo's says orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, that rodent C-cell tumors are considered GLP-1 receptor-dependent effects in products pharmacologically active in those species, and that while orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of those rodent tumors has not been determined. The full anatomy of that warning is in The Boxed Warning on Your GLP-1 Label, Explained.

One printed exit exists on one label only. If a patient does not tolerate the 25 mg once daily Wegovy tablet maintenance dosage, the label says to consider switching to Wegovy injection 1.7 mg once weekly. Foundayo is sold only as a tablet, so its label offers no such move. Between the ritual, the ladder and the fine print, the two daily pills for weight turn out to ask for nearly opposite days from the people who take them, and the person best placed to weigh those asks against a real life is the prescriber holding the prescription pad.

Frequently asked questions

Are Foundayo and Wegovy tablets the same medicine?

No. Wegovy tablets contain semaglutide and Foundayo contains orforglipron, two different molecules, though both are daily oral treatments in the GLP-1 family approved for weight management in adults. Because the molecules differ, the dosing scales, the daily rules and the interaction warnings are not comparable between them.

Does Foundayo have the empty stomach rule?

No. The empty stomach ritual belongs to Wegovy tablets: one tablet in the morning on an empty stomach with water, up to 4 ounces, and no other liquid, then at least 30 minutes before food, beverages or other oral medicines. Foundayo is taken orally once daily with or without food, swallowed whole, no more than one tablet a day, and its label sets no water rule and no waiting period.

Which pill has the higher maximum dose?

The numbers are not comparable, because they measure different molecules. Wegovy tablets reach a single destination, the 25 mg maintenance dosage, from day 91. Foundayo reaches a maximum of 17.2 mg once daily, and its label allows optional increases to 9, 14.5 or 17.2 mg after at least 30 days on the current dosage, based on treatment response and tolerability.

What does each label say about a missed dose?

The rules point in opposite directions. For Wegovy tablets, skip the missed dose and take the next dose the following day. For Foundayo, take the dose as soon as possible, do not double up the next dose, and if 7 or more consecutive doses are missed, restart dosage escalation at a lower dosage. A prescriber should guide any restarted schedule.

Do both pills carry the thyroid boxed warning?

Yes, both carry the same boxed warning about thyroid C-cell tumors and the same contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2. The stated premise differs: Wegovy's warning says semaglutide causes these tumors in rodents at clinically relevant exposures and that human risk is unknown, while Foundayo's says orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents.